JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $29 to $28.
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.